Related Experiment Videos
[Clinical studies on flomoxef in acute tonsillitis]
1Department of Otolaryngology, Suibaragou Hospital.
The Japanese Journal of Antibiotics
|September 1, 1994
Summary
Flomoxef (FMOX) demonstrates strong antibacterial action against acute tonsillitis pathogens. Clinical trials show high efficacy and usefulness, with a 75% clinical efficacy rate and a 83% usefulness rate.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Microbiology
Background:
- Acute tonsillitis is a common infection requiring effective antibiotic treatment.
- Flomoxef (FMOX) is a potential therapeutic agent for bacterial infections.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of Flomoxef (FMOX) in treating acute tonsillitis.
- To determine the antimicrobial susceptibility of clinical strains to FMOX.
Main Methods:
- Assessed the 80% minimum inhibitory concentration (MIC) of FMOX against Gram-positive, Gram-negative, and anaerobic bacteria.
- Conducted a clinical trial involving 30 patients with acute tonsillitis treated with FMOX.
- Evaluated clinical effectiveness, bacteriological response, safety, and overall usefulness of FMOX.
Main Results:
- FMOX exhibited broad-spectrum antibacterial activity with an 80% MIC of 0.39 microgram/ml.
- Clinical efficacy rate was 75% (21/28), with high bacterial elimination rates (67-100%).
- Adverse events were mild (6%), and the overall usefulness rate was 83%.
Conclusions:
- Flomoxef (FMOX) demonstrates significant clinical efficacy and a favorable safety profile for acute tonsillitis.
- FMOX is considered a highly useful antibiotic for treating severe acute tonsillitis.